title: 52nd Annual Scientific Session of the American College of Cardiology, Chicago, March 30-April 2, 2003.
authors.affiliation: glynnowen@macline.co.uk
authors.forename: Olwen Glynn
authors.initials: OG
authors.lastname: Owen
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001384:Azetidines / Q000627:therapeutic use; D001596:Benzylamines; D002309:Cardiology; D002318:Cardiovascular Diseases / Q000517:prevention & control; D002641:Chicago; D002986:Clinical Trials as Topic; D000069438:Ezetimibe; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D011743:Pyrimidines; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides
chemical_list: D000925:Anticoagulants; D001384:Azetidines; D001596:Benzylamines; D005464:Fluorobenzenes; D000960:Hypolipidemic Agents; D011743:Pyrimidines; D013449:Sulfonamides; C426686:ximelagatran; D000068718:Rosuvastatin Calcium; D000069438:Ezetimibe